Vanguard Group’s UroGen Pharma URGN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.49M | Buy |
254,971
+4,542
| +2% | +$62.2K | ﹤0.01% | 3329 |
|
|
2025
Q1 | $2.77M | Sell |
250,429
-46,925
| -16% | -$519K | ﹤0.01% | 3379 |
|
|
2024
Q4 | $3.17M | Buy |
297,354
+12,917
| +5% | +$138K | ﹤0.01% | 3430 |
|
|
2024
Q3 | $3.61M | Buy |
284,437
+60,455
| +27% | +$768K | ﹤0.01% | 3385 |
|
|
2024
Q2 | $3.76M | Buy |
223,982
+29,016
| +15% | +$487K | ﹤0.01% | 3372 |
|
|
2024
Q1 | $2.92M | Buy |
194,966
+24,367
| +14% | +$366K | ﹤0.01% | 3477 |
|
|
2023
Q4 | $2.56M | Buy |
170,599
+58,765
| +53% | +$881K | ﹤0.01% | 3514 |
|
|
2023
Q3 | $1.57M | Buy |
111,834
+12,019
| +12% | +$168K | ﹤0.01% | 3673 |
|
|
2023
Q2 | $1.03M | Buy |
+99,815
| New | +$1.03M | ﹤0.01% | 3889 |
|
|
2022
Q2 | – | Sell |
-106,468
| Closed | -$927K | – | 4636 |
|
|
2022
Q1 | $927K | Sell |
106,468
-248
| -0.2% | -$2.16K | ﹤0.01% | 4231 |
|
|
2021
Q4 | $1.02M | Buy |
106,716
+3,518
| +3% | +$33.5K | ﹤0.01% | 4261 |
|
|
2021
Q3 | $1.74M | Buy |
103,198
+6,828
| +7% | +$115K | ﹤0.01% | 4102 |
|
|
2021
Q2 | $1.47M | Buy |
96,370
+3,647
| +4% | +$55.7K | ﹤0.01% | 4055 |
|
|
2021
Q1 | $1.81M | Buy |
92,723
+9,494
| +11% | +$185K | ﹤0.01% | 3885 |
|
|
2020
Q4 | $1.5M | Buy |
83,229
+8,304
| +11% | +$150K | ﹤0.01% | 3726 |
|
|
2020
Q3 | $1.45M | Sell |
74,925
-3,080
| -4% | -$59.4K | ﹤0.01% | 3578 |
|
|
2020
Q2 | $2.04M | Sell |
78,005
-3,220
| -4% | -$84.1K | ﹤0.01% | 3426 |
|
|
2020
Q1 | $1.45M | Buy |
81,225
+636
| +0.8% | +$11.4K | ﹤0.01% | 3387 |
|
|
2019
Q4 | $2.69M | Sell |
80,589
-1,419
| -2% | -$47.4K | ﹤0.01% | 3358 |
|
|
2019
Q3 | $1.95M | Buy |
82,008
+11,709
| +17% | +$279K | ﹤0.01% | 3456 |
|
|
2019
Q2 | $2.53M | Buy |
70,299
+62,778
| +835% | +$2.26M | ﹤0.01% | 3404 |
|
|
2019
Q1 | $278K | Buy |
+7,521
| New | +$278K | ﹤0.01% | 3866 |
|
|
2018
Q3 | – | Sell |
-4,163
| Closed | -$208K | – | 4174 |
|
|
2018
Q2 | $208K | Buy |
+4,163
| New | +$208K | ﹤0.01% | 3973 |
|